Risk of nephrolithiasis with finerenone versus other chronic kidney disease medications: a comparative real-world evidence study
- 1School of Medicine, College of Medicine, National Cheng Kung University
- 2Department of Medical Education, National Cheng Kung University Hospital
- 3Department of Urology, National Cheng Kung University Hospital
Abstract
Finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA), has shown renoprotective benefits for chronic kidney disease (CKD) in people with type 2 diabetes (T2DM); however, its impact on nephrolithiasis remains unexplored. This study compared the risk of incident nephrolithiasis between patients treated with finerenone, spironolactone, or other standard CKD pharmacological therapies. We conducted a new-user, active-comparator retrospective cohort study using the TriNetX US Collaborative Network from June 1, 2021 to June 1, 2024. Adult finerenone initiators were compared with 1:1 propensity-score matched (PSM) cohorts initiating spironolactone, SGLT2 inhibitors (SGLT2i), or Angiotensin-Converting enzyme inhibitors/Angiotensin II receptor blockers (ACEi/ARB). The primary outcome was nephrolithiasis diagnosis (ICD 10: N20-N23) occurring between 4 and 16 months after medication initiation, evaluated using Cox models and time-varying analyses. After PSM, finerenone was associated with a significantly higher risk of incident nephrolithiasis compared to spironolactone (hazard ratio [HR]: 1.328, 95% CI: 1.065–1.657), SGLT2i (HR: 1.483, 95% CI: 1.118–1.967), and ACEi/ARB (HR: 1.495, 95% CI: 1.145–1.953), representing a 32.8%, 48.3%, 49.5% higher relative risk respectively. This increased risk remained consistent across subgroups, including CKD, T2DM, and hypertension. Among patients with T2DM already receiving SGLT2i, the addition of finerenone was significantly associated with an increased stone risk compared to SGLT2i monotherapy. Conclusively, finerenone is associated with a higher incidence of new-onset nephrolithiasis, and it may influence the potential stone-protective effects of SGLT2i.
Related
- Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY)
- Undiagnosed Chronic Kidney Disease, Outcomes, and Finerenone in Heart Failure
- Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases
- Management of Chronic Antihypertensive Medications in the Perioperative Period
- Real-world safety profile of finerenone in patients with type 2 diabetes and chronic kidney disease: a multi-database pharmacovigilance analysis of the FAERS and JADER systems
BibTeX
@article{chen2026risk,
title = {{Risk of nephrolithiasis with finerenone versus other chronic kidney disease medications: a comparative real-world evidence study}},
author = {Yi-Hong Chen and Tung-Liang Hwang and Ze-Hong Lu and Chan-Jung Liu},
journal = {Scientific Reports},
year = {2026},
month = aug,
doi = {10.1038/s41598-026-65475-8},
url = {https://doi.org/10.1038/s41598-026-65475-8},
note = {CC BY},
}
RIS
TY - JOUR
TI - Risk of nephrolithiasis with finerenone versus other chronic kidney disease medications: a comparative real-world evidence study
AU - Yi-Hong Chen
AU - Tung-Liang Hwang
AU - Ze-Hong Lu
AU - Chan-Jung Liu
PY - 2026
DA - 2026/08/01
JO - Scientific Reports
DO - 10.1038/s41598-026-65475-8
UR - https://doi.org/10.1038/s41598-026-65475-8
AB - Finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA), has shown renoprotective benefits for chronic kidney disease (CKD) in people with type 2 diabetes (T2DM); however, its impact on nephrolithiasis remains unexplored. This study compared the risk of incident nephrolithiasis between patients treated with finerenone, spironolactone, or other standard CKD pharmacological therapies. We conducted a new-user, active-comparator retrospective cohort study using the TriNetX US Collaborative Network from June 1, 2021 to June 1, 2024. Adult finerenone initiators were compared with 1:1 propensity-score matched (PSM) cohorts initiating spironolactone, SGLT2 inhibitors (SGLT2i), or Angiotensin-Converting enzyme inhibitors/Angiotensin II receptor blockers (ACEi/ARB). The primary outcome was nephrolithiasis diagnosis (ICD 10: N20-N23) occurring between 4 and 16 months after medication initiation, evaluated using Cox models and time-varying analyses. After PSM, finerenone was associated with a significantly higher risk of incident nephrolithiasis compared to spironolactone (hazard ratio [HR]: 1.328, 95% CI: 1.065–1.657), SGLT2i (HR: 1.483, 95% CI: 1.118–1.967), and ACEi/ARB (HR: 1.495, 95% CI: 1.145–1.953), representing a 32.8%, 48.3%, 49.5% higher relative risk respectively. This increased risk remained consistent across subgroups, including CKD, T2DM, and hypertension. Among patients with T2DM already receiving SGLT2i, the addition of finerenone was significantly associated with an increased stone risk compared to SGLT2i monotherapy. Conclusively, finerenone is associated with a higher incidence of new-onset nephrolithiasis, and it may influence the potential stone-protective effects of SGLT2i.
SN - 2045-2322
ER -